List in chronological order recent news for axsm

Here is a chronological list of recent news about AXSM: 1. **September 14, 2024**: Director Mark E. Saad sold 11,016 shares of Axsome Therapeutics at an average price of $91.31, totaling $1,005,870.96. Following the sale, the director owns 10,002 shares. 2. **September 11, 2024**: Axsome Therapeutics was given a consensus recommendation of "Buy" from the 14 brokerages covering the firm, with an average 12-month price objective of $124.57. 3. **September 6, 2024**: Cantor Fitzgerald reaffirmed an "overweight" rating on AXSM with a price target of $107.00. 4. **August 6, 2024**: UBS Group reduced their price target from $107.00 to $105.00 and maintained a "buy" rating. 5. **June 12, 2024**: Mizuho reiterated a "buy" rating and set a price target of $106.00. 6. **September 3, 2024**: Wells Fargo & Company initiated coverage on AXSM with an "overweight" rating and a price target of $140.00. 7. **September 5, 2024**: HC Wainwright restated a "buy" rating and issued a price target of $180.00. 8. **August 14, 2024**: StockNews.com downgraded AXSM from a "hold" to a "sell" rating. 9. **July 22, 2024**: Axsome Therapeutics reported a quarterly earnings per share (EPS) of ($1.24), surpassing the consensus estimate of ($1.30) by $0.06. 10. **September 16, 2024**: Sofinnova Investments Inc. purchased shares of Axsome Therapeutics during the second quarter, buying 310,198 shares valued at approximately $24,971,000. This chronological list covers the most recent news about AXSM, including investments, broker ratings and price targets, a director sale, and the company's financial performance.